ID Biomedical (NASDAQ:IDBE)
Historical Stock Chart
From May 2019 to May 2024
ID Biomedical closes sale and leaseback transactions
VANCOUVER, March 4 /PRNewswire-FirstCall/ -- ID Biomedical Corporation (TSX:
IDB; NASDAQ: IDBE) announced today that it has closed the transactions with
Alexandria Real Estate Equities, Inc. (NYSE:ARE) for the sale and leaseback of
two ID Biomedical facilities: the newly constructed Vaccine Research Centre in
Laval, Quebec, Canada; and a vaccine development facility in Northborough,
Massachusetts, U.S. The total purchase price paid at closing to ID Biomedical
is approximately CAD $50 million. All conditions precedent to these
transactions have now been satisfied.
ID Biomedical will lease each of these properties from Alexandria for a period
of 15 years. In addition, at each site ID Biomedical has secured three,
five-year options to extend the leases beyond the original term, meaning the
Company has the option of maintaining its business operations at each facility
for up to 30 years.
About ID Biomedical
ID Biomedical is an integrated biotechnology company dedicated to the
development of innovative vaccine products. It operates in research,
development, manufacturing, sales and marketing from its facilities in Canada
and in the United States. ID Biomedical is dedicated to becoming a premier
vaccine company with significant marketed products worldwide and an extensive
pipeline in both clinical and preclinical development.
ID Biomedical has a leading position in the Canadian influenza market. It
received a ten-year mandate from the Government of Canada in 2001 to assure a
state of readiness in the case of an influenza pandemic and provide influenza
vaccine for all Canadians in such an event. It also currently supplies
approximately 75% of the Canadian government's influenza vaccine purchases.
For further information on ID Biomedical, please visit the Company's website at
http://www.idbiomedical.com/.
About Alexandria Real Estate Equities
Alexandria Real Estate Equities, Inc. is the pre-eminent real estate investment
trust focused principally on the ownership, operation, management, acquisition,
expansion and redevelopment and selective development of properties containing
office/laboratory space. Alexandria has an outstanding track record for almost
eight-years as an NYSE listed company with a total market capitalization as of
December 31, 2004 of US$2.85 billion. Alexandria provides high-quality
laboratory facilities, services and capital to the broad and diverse life
science sector. Alexandria's national operating platform is based on the
principle of "clustering" with assets and operations strategically located in
key life science hub markets.
The information in this news release contains so-called "forward-looking"
statements. These include statements regarding ID Biomedical's expectations and
plans relating to the integration of the vaccine business acquired from Shire,
statements about ID Biomedical's expectations, beliefs, intentions or
strategies for the future, which may be indicated by words or phrases such as
"anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical
believes", "management believes", and similar language. All forward-looking
statements are based on ID Biomedical's current expectations and are subject to
risks and uncertainties and to assumptions made. Important factors that could
cause actual results to differ materially from those expressed or implied by
such forward-looking statements include: (i) the company's ability to
successfully integrate the Shire vaccine business; (ii) the company's ability
to successfully complete preclinical and clinical development of its products;
(iii) the company's ability to manufacture its products; (iv) the seasonality
of the flu-vaccine business and related fluctuations in the company's revenues
from quarter to quarter; (v) decisions, and the timing of decisions, made by
the health regulatory agencies regarding approval of its products for human
testing; (vi) the company's ability to enter into distribution agreements for
its products, and to complete and maintain corporate alliances relating to the
development and commercialization of its technology and products; (vii) market
acceptance of its technologies and products; and (viii) the competitive
environment and impact of technological change and other risks detailed in the
company's filings with the Securities and Exchange Commission. ID Biomedical
bases its forward-looking statements on information currently available to it,
and assumes no obligation to update them.
For further information, please contact:
Investor Relations / Media
Dean Linden
(604) 431-9314
Michele Roy
(450) 978-6313
DATASOURCE: ID Biomedical Corporation
CONTACT: Investor Relations/Media, Dean Linden, (604) 431-9314,
; Michele Roy, (450) 978-6313,
;
To request a free copy of this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.